Simultaneous Detection of Drug-Induced Liver Injury Protein and microRNA Biomarkers Using Dynamic Chemical Labelling on a Luminex MAGPIX System
MetadataShow full item record
AuthorMarín Romero, Antonio; Tabraue Chávez, Mavys; López-Longarela, Barbara; Fara, Mario A.; Sánchez Martín, Rosario María; Díaz Mochón, Juan José; Pernagallo, Salvatore
Dynamic chemical labelling (DCL)Drug-induced liver injury (DILI)miRNA-122Luminex MAGPIXLiquid biopsyAntibody-dependant method
Marín-Romero, A.; Tabraue-Chávez, M.; López-Longarela, B.; Fara, M.A.; Sánchez-Martín, R.M.; Dear, J.W.; Ilyine, H.; Díaz-Mochón, J.J.; Pernagallo, S. Simultaneous Detection of Drug-Induced Liver Injury Protein and microRNA Biomarkers Using Dynamic Chemical Labelling on a Luminex MAGPIX System. Analytica 2021, 2, 130–139. https://doi.org/ 10.3390/analytica2040013
Drug-induced liver injury (DILI) is a potentially fatal adverse event and a leading cause for pre- and post-marketing drug withdrawal. Several multinational DILI initiatives have now recommended a panel of protein and microRNA (miRNA) biomarkers that can detect early liver injury and inform about mechanistic basis. This manuscript describes the development of seqCOMBO, a unique combo-multiplexed assay which combines the dynamic chemical labelling approach and an antibody-dependant method on the Luminex MAGPIX system. SeqCOMBO enables a versatile multiplexing platform to perform qualitative and quantitative analysis of proteins and miRNAs in patient serum samples simultaneously. To the best of our knowledge, this is the first method to profile protein and miRNA biomarkers to diagnose DILI in a single-step assay.